GUARNERI, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.150
EU - Europa 8.980
AS - Asia 8.751
SA - Sud America 1.343
Continente sconosciuto - Info sul continente non disponibili 255
AF - Africa 212
OC - Oceania 16
Totale 40.707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.679
IT - Italia 2.790
SG - Singapore 2.623
CN - Cina 2.223
GB - Regno Unito 1.955
HK - Hong Kong 1.064
BR - Brasile 1.007
IE - Irlanda 865
VN - Vietnam 816
SE - Svezia 745
DE - Germania 625
BD - Bangladesh 590
FI - Finlandia 412
UA - Ucraina 402
RU - Federazione Russa 303
FR - Francia 289
CA - Canada 254
TR - Turchia 246
KR - Corea 242
IN - India 234
BG - Bulgaria 146
ID - Indonesia 142
AR - Argentina 106
NL - Olanda 95
JP - Giappone 92
MX - Messico 86
IQ - Iraq 69
ES - Italia 56
ZA - Sudafrica 56
PL - Polonia 55
CO - Colombia 54
PK - Pakistan 48
AE - Emirati Arabi Uniti 45
EC - Ecuador 42
VE - Venezuela 41
PH - Filippine 40
CL - Cile 34
LT - Lituania 34
MY - Malesia 33
BE - Belgio 30
CR - Costa Rica 29
UZ - Uzbekistan 28
SA - Arabia Saudita 26
AT - Austria 24
MA - Marocco 24
PY - Paraguay 24
EG - Egitto 23
JM - Giamaica 22
IR - Iran 20
JO - Giordania 19
TW - Taiwan 19
TH - Thailandia 18
CZ - Repubblica Ceca 17
HU - Ungheria 16
KE - Kenya 16
AU - Australia 15
ET - Etiopia 15
GR - Grecia 15
AZ - Azerbaigian 14
CH - Svizzera 14
TN - Tunisia 14
BO - Bolivia 13
DZ - Algeria 13
AL - Albania 12
HN - Honduras 12
NG - Nigeria 12
PT - Portogallo 12
TT - Trinidad e Tobago 12
DO - Repubblica Dominicana 11
KZ - Kazakistan 11
LB - Libano 11
OM - Oman 11
NP - Nepal 10
RO - Romania 10
PE - Perù 9
UY - Uruguay 9
RS - Serbia 8
SN - Senegal 8
BB - Barbados 7
EU - Europa 7
IL - Israele 7
PA - Panama 7
QA - Qatar 7
SC - Seychelles 7
SV - El Salvador 7
CI - Costa d'Avorio 6
CY - Cipro 6
MD - Moldavia 6
NI - Nicaragua 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
EE - Estonia 5
LV - Lettonia 5
MK - Macedonia 5
PR - Porto Rico 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
DK - Danimarca 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
Totale 40.389
Salva come PNG Salva come JPEG
Città #
Ashburn 2.391
Santa Clara 1.842
Singapore 1.744
Fairfield 1.457
Southend 1.136
Woodbridge 1.095
Hong Kong 1.043
San Jose 980
Chandler 917
Houston 897
Dublin 861
Jacksonville 738
Council Bluffs 713
Dearborn 622
Ann Arbor 582
Seattle 555
Wilmington 518
Beijing 517
Hefei 509
Cambridge 485
Nyköping 434
London 381
Los Angeles 377
New York 333
Chicago 305
Milan 300
The Dalles 286
Helsinki 266
Ho Chi Minh City 250
Modena 232
Seoul 210
Hanoi 200
Rome 189
San Diego 172
Princeton 156
Sofia 139
Columbus 132
Eugene 131
Lauterbourg 131
Izmir 126
Buffalo 123
Dallas 119
Moscow 113
Jakarta 104
Salt Lake City 104
São Paulo 104
Munich 103
Shanghai 102
Naples 81
Phoenix 66
Toronto 65
Boardman 64
Tokyo 63
Bologna 61
Des Moines 59
Atlanta 58
Falls Church 58
Frankfurt am Main 57
Turin 55
Elk Grove Village 52
Orem 51
Tampa 51
Denver 47
Florence 47
Da Nang 43
Bari 42
Dong Ket 41
Norwalk 40
Bremen 37
Haiphong 37
Montreal 35
Redwood City 35
Warsaw 34
Brooklyn 32
Chennai 32
Guangzhou 32
Palermo 32
Fremont 31
Genoa 31
Boston 29
Mexico City 29
Mumbai 28
Redondo Beach 28
Miami 27
Newark 27
Rio de Janeiro 27
Turku 27
Charlotte 26
Nanjing 26
North Bergen 25
Tashkent 25
Brussels 24
Catania 24
Curitiba 24
Kunming 24
Miano 24
Ottawa 24
San Mateo 24
Verona 24
Amsterdam 23
Totale 27.232
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.184
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 512
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 447
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 441
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 434
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 421
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 409
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 407
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 404
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 402
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 394
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 393
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 377
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 373
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 365
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 362
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 356
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 355
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 345
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 344
Achievements and unmet needs in the management of advanced ovarian cancer 343
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 342
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 341
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 336
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 335
Detection of microparticles from human red blood cells by multiparametric flow cytometry 333
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 330
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 330
Biomarker expression and survival after primary chemotherapy for breast cancer. 329
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 327
Immune characterization of breast cancer metastases: prognostic implications. 326
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 325
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors 325
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 322
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 318
Trastuzumab containing regimens for early breast cancer. 318
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 316
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 315
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 314
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 312
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 303
The curability of breast cancer and the treatment of advanced disease 302
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 295
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 292
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 290
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 289
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 289
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 286
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 285
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 283
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 283
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 279
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 276
Biomarkers predicting clinical benefit: fact or fiction? 272
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 272
Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer 271
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 268
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 268
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 267
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 265
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 263
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 261
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 261
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 260
Bone metastases- Pharmacological treatment 259
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy 258
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 257
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 257
Final results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarker evaluation in operable breast cancer 257
Timing for starting second-line therapy in recurrent ovarian cancer 256
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 255
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 252
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 250
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 250
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 250
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 249
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 249
Trastuzumab-containing regimens for metastatic breast cancer 248
Tumori ginecologici 247
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer 244
Bevacizumab treatment for advanced breast cancer. 244
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer 242
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 241
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 241
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 240
Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastases treated for up to ten years 239
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 234
Triple-negative breast cancer: current management and future options. 234
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 234
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 232
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 227
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 227
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 226
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 226
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 223
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 222
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 222
The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer 219
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study 219
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 219
Totale 30.591
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.395
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.734 0 0 0 108 64 135 149 119 278 202 394 285
2022/20233.462 331 307 174 248 282 375 52 248 1.156 48 137 104
2023/20242.185 98 131 120 134 324 172 169 437 75 115 161 249
2024/20256.106 185 117 106 483 1.214 1.089 323 387 673 314 488 727
2025/202612.607 705 405 882 1.326 1.982 838 1.514 646 1.136 1.243 1.075 855
2026/20273.743 584 904 1.009 1.246 0 0 0 0 0 0 0 0
Totale 40.707